Antibody-drug conjugates (ADCs) belong to a new class of highly potent biopharmaceutical drugs designed as targeted therapy for the treatment of cancer patients. A typical ADC consists of three components: a target specific monoclonal antibody attached to a cytotoxic drug by the chemical linker. The antibody specifically targets a certain tumor marker (e.g. a protein that, ideally, is only to be found in or on tumor cells) , track this protein in the body and attach itself to the surface of cancer cell. The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the tumor cell, which then absorbs or internalizes the antibody together with the cytotoxin. After the ADC is internalized, the cytotoxic drug is released and kills the cancer cell. Typical examples are Brentuximab vedotin (SGN35), Trastuzumab-emtansine (T-DM1), Inotuzumab ozogamicin (CMC-544) and Gemtuzumab ozogamicin.
Creative Biolabs scientists are focusing on applying excellent science and technology to discover and develop potential new ADCs with the goal of becoming first-in-class therapeutics. We also provide custom ADCs design and construction services. Besides expression and purification of ADCs, we also provided HPLC/ELISA/TFC-MS/MS analysis for free drug and pharmacokinetics research.
Featured Products